LOXL2 and non-small cell lung carcinoma: Figure S4 showed the relationship between RTKN2, NFIX, PTX3, BMP2, and LOXL2 mutation status and clinicopathological characteristics of NSCLC patients. In addition, the expression levels of RTKN2, NFIX, PTX3, BMP2 and LOXL2 were correlated with poor prognosis of NSCLC patients in the PrognoScan and Kaplan-Meier Plotter databases (Figure S5 and Table 4). Therefore, we grouped the median values of RTKN2, NFIX, PTX3, BMP2, and LOXL2 expression to construct a nomogram to assess the prognosis of patients (Figure 9).